Celgene International Sàrl, a subsidiary of Celgene Corporation, CELG announced that based on the recommendation from the Data Monitoring
Committee it will discontinue its pivotal double-blinded Phase III
MAINSAIL trial that was designed to evaluate the efficacy and safety of
docetaxel and prednisone with or without lenalidomide in patients with
castrate-resistant prostate cancer.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in